Coherus Biosciences traded at $1.65 this Monday March 2nd, decreasing $0.02 or 1.20 percent since the previous trading session. Looking back, over the last four weeks, Coherus Biosciences lost 25.68 percent. Over the last 12 months, its price rose by 64.18 percent. Looking ahead, we forecast Coherus Biosciences to be priced at 1.62 by the end of this quarter and at 1.47 in one year, according to Trading Economics global macro models projections and analysts expectations.
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.